Meet EMMA
Optimizing Aortic Compression in Postpartum Hemorrhage
Innovation
How Can EMMA Improve Maternity Care?
At the forefront of life-saving technologies for postpartum hemorrhage
Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide, with approximately 14 million women affected each year, resulting in nearly 70,000 deaths according to the World Health Organization (WHO). Studies indicate that timely intervention with effective bleeding control can reduce maternal mortality rates by up to 90%. Today's management of postpartum hemorrhage involves the WHO recommended procedure of manually compressing the abdominal aorta to control hemorrhage.
The EMMA Bleeding Stabilizer is designed to improve this critical procedure, providing immediate and reliable bleeding control and hemodynamic stabilization. With safe, resilient and tolerable compression of the abdominal aorta, EMMA frees up healthcare providers to perform other essential tasks. EMMA also enables continuous compression during transport and transvaginal procedures keeping the patient physiologically stabilized.
By standardizing aortic compression with the application of EMMA, we aim to significantly reduce the occurrence of massive bleeding events and help mitigate the risks associated with severe blood loss. By offering conservative treatments for PPH more time to take effect, EMMA potentially decreases the need for invasive and resource-intensive interventions. Most importantly, with EMMA, no mother should have to lose her life to PPH.
Core Traits of the EMMA Bleeding Stabilizer
With EMMA as a team member during critical PPH, you achieve immediate patient stabilization which supports conservative treatments and prevents escalation into a life-threatening and traumatic situation of massive blood loss.
Ease of Use: Intuitive design ensures quick application in any setting, minimizing training requirements and ensuring broad applicability.
Universal Fit: Applicable across various BMI and body types.
Auto regulated pressure: Built-in mechanism for optimal pressure control ensures effective hemostasis without collateral damage.
Atraumatic Design: Aortic compression with minimized shear force and vessel wall trauma, at the same time reducing patient discomfort.
Non-Invasive: Minimizes the risk of complications, requires no sterile conditions and is quickly restored for reuse.
Hemodynamic Stabilization: Provides circulatory support and blood pressure stabilization.
Scientific Background
Zerocyte is uniquely positioned to design a device for targeted aortic compression. Since 2013, our research at Karolinska Institutet has focused on methods to control lethal blood loss by modulating aortic blood flow. Extensive translational research, which has led to several publications in high-impact journals, enabled us to design the EMMA Bleeding Stabilizer.
Although simple to use, EMMA performs a critical physiological effect that, if done improperly, could lead to serious complications. Our expertise and clinical guidance ensure EMMA's safe and effective use. The design of EMMA Bleeding Stabilizer is evidence-based, addressing challenges like respiratory and circulatory side effects, ischemic injuries and pain. Our ongoing commitment to research will ensure that EMMA becomes a trusted tool in maternal healthcare.
